Date:2022.10.01
Your Name:Jian-Guo Guo
Manuscript Title:_MicroRNA-155-5p inhibition alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1
expression_
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	None	planning of the work
1	manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	None
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	None
4	Consulting fees	None	None

5	Payment or honoraria for lectures, presentations,	None	None
	speakers bureaus, manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Support for attending meetings and/or travel	None	None
8	Patents planned, issued or	None	None
	pending		
9	Participation on a Data	None	None
	Safety Monitoring Board or	Hone	The first of the f
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	None	None
	group, paid or unpaid		
11	Stock or stock options	None	None
4.0	D	N	
12	Receipt of equipment, materials, drugs, medical	None	None
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:2022.10.	01
Your Name:	_Ruefeng Rao
Manuscript Title	:_MicroRNA-155-5p inhibition alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1
expression_	
Manuscript num	ber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	None
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	None
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	None
4	Consulting fees	None	None
5	Payment or honoraria for	None	None

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
	cestimony		
7	Commont for ottomaling	Nama	None
/	Support for attending	None	None
	meetings and/or travel		
8	Patents planned, issued or	None	None
°	pending	None	Notice
	perioring		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

Date:2022.10.01	
Your Name:Jun Jiang	
Manuscript Title:_MicroRNA-155-5p inhibitior	alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1
expression_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials,	None	None
	medical writing, article processing charges, etc.) No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None
5	Payment or honoraria for	None	None

	lasturas procentations		
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
7	Support for attending	None	None
	meetings and/or travel		
8	Patents planned, issued or	None	None
	pending		1.66
	Fe.1.38		
9	Participation on a Data	None	None
	Safety Monitoring Board or	146112	Hene
	Advisory Board		
10	Leadership or fiduciary role	None	None
10	in other board, society,	None	None
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
11	Stock of Stock options	None	None
12	Descipt of aguinment	Nego	None
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
12	Services	Hana7han Dunan Maritari	are when to a
13	Other financial or non-	HangZhou Dunen Medical	employee
	financial interests	Laboratory Co., Ltd.	

The author is from HangZhou Dunen Medical Laboratory Co., Ltd.			

Please place an "X" next to the following statement to indicate your agreement:

Date:2022.10.01	
Your Name:Xin Li	
Manuscript Title:_MicroRNA-155-5p inhibition alleving	iates irritable bowel syndrome by increasing claudin-1 and ZO-1
expression_	
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	None
3	Royalties or licenses	None	None
4	Consulting fees	None	None
5	Payment or honoraria for	None	None

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
	cestimony		
7	Commont for ottomaling	Nana	None
/	Support for attending	None	None
	meetings and/or travel		
8	Patents planned, issued or	None	None
°	pending	None	Notice
	perioring		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
11	Stock of Stock options	None	Notice
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement:

Date:2022.10	.01
Your Name:	_Shengmei Zhu
Manuscript Title	e:_MicroRNA-155-5p inhibition alleviates irritable bowel syndrome by increasing claudin-1 and ZO-1
expression_	
Manuscript nun	nber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	None
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	None
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	None
4	Consulting fees	None	None
5	Payment or honoraria for	None	None

	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	None
	testimony		
	cestimony		
7	Commont for ottomaling	Nana	None
/	Support for attending	None	None
	meetings and/or travel		
8	Patents planned, issued or	None	None
°	pending	None	Notice
	perioring		
9	Participation on a Data	None	None
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	None
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	None
11	Stock of Stock options	None	Notice
12	Receipt of equipment,	None	None
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	None
	financial interests		

None

Please place an "X" next to the following statement to indicate your agreement: